

Hizentra – CSL Behring

CSL Behring announced a patient-level withdrawal of one lot of Hizentra [immune globulin subcutaneous (human)] due to an increased frequency of reports of injection-site reactions and local hypersensitivity-type of events after administration.

Product	Hizentra
Manufacturer	CSL Behring
Withdrawal identification date	01/03/2022
Affected NDCs	44206-0455-10

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.